---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020964"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:39:03.556985+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Oragenics appoints Dr. William Peacock as Chief Clinical Officer for Phase II concussion trial

## Summary
- Appointed Dr. William 'Frank' Peacock as Chief Clinical Officer effective May 22, 2024.
- Dr. Peacock will oversee upcoming Phase II trial of ONP-002 for concussion in emergency departments.
- Dr. Peacock is Vice Chair for Emergency Medicine Research at Baylor College of Medicine.
- ONP-002, a new chemical entity delivered intranasally, showed safety in Phase I; Phase II planned.
- Concussion is an unmet need with ~69M cases annually; post-concussion syndrome occurs in up to 20% of patients.

## SEC filing metadata
- accession: 0001493152-24-020964
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315224020964/0001493152-24-020964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315224020964/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020964
- JSON: https://secwatch.observer/filing/0001493152-24-020964.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.